Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Paul Grint, Bruce Huebner, Thomas McLain

Premium

Illumina said in a recent filing with the US Securities and Exchange Commission that Paul Grint plans to retire from the firm's board of directors, effective as of the next Illumina stockholder meeting.

Grint has been a director since 2005. He's currently senior vice president at Forest Research Institute, and was previously the chief medical officer at Kalypsys. He has also served as an executive at Zephyr Sciences, Pfizer, IDEC Pharmaceuticals, and Schering-Plough.


Vermillion has appointed Bruce Huebner to be company chairman. Huebner had been serving as Vermillion's interim CEO and president until earlier this month when the company earlier named Thomas McLain to those positions.

Prior to joining Vermillion, Huebner held various managerial posts in the life sciences and healthcare industries. From 2005 to 2008, he served as president of Osmetech Molecular Diagnostics, now GenMark Diagnostics. And from 2002 and 2004, he was president and chief operating officer of Nanogen.

The Scan

Wolf Howl Responses Offer Look at Vocal Behavior-Related Selection in Dogs

In dozens of domestic dogs listening to wolf vocalizations, researchers in Communication Biology see responses varying with age, sex, reproductive status, and a breed's evolutionary distance from wolves.

Facial Imaging-Based Genetic Diagnoses Appears to Get Boost With Three-Dimensional Approach

With data for more than 1,900 individuals affected by a range of genetic conditions, researchers compared facial phenotype-based diagnoses informed by 2D or 3D images in the European Journal of Human Genetics.

Survey Suggests Multigene Cancer Panel VUS Reporting May Vary Across Genetic Counselors

Investigators surveyed dozens of genetic counselors working in clinical or laboratory settings, uncovering attitudes around VUS reporting after multigene cancer panel testing in the Journal of Genetic Counseling.

Study Points to Tuberculosis Protection by Gaucher Disease Mutation

A mutation linked to Gaucher disease in the Ashkenazi Jewish population appears to boost Mycobacterium tuberculosis resistance in a zebrafish model of the lysosomal storage condition, a new PNAS study finds.